Lataa...
Sorafenib and entecavir: The dioscuri of treatment for advanced hepatocellular carcinoma?
Hepatitis B virus (HBV) is responsible for 50%-80% of cases of hepatocellular carcinoma (HCC) worldwide. Entecavir (ET) is a potent inhibitor of chronic HBV-DNA polymerase, inhibiting both the priming and elongation steps of viral DNA replication. Sorafenib (SO) has proven efficacy in prolonging sur...
Tallennettuna:
| Päätekijät: | , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Baishideng Publishing Group Co., Limited
2013
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3627877/ https://ncbi.nlm.nih.gov/pubmed/23599639 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v19.i14.2141 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|